Sarepta TherapeuticsSRPT
SRPT
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
19% more call options, than puts
Call options by funds: $285M | Put options by funds: $240M
8% more repeat investments, than reductions
Existing positions increased: 168 | Existing positions reduced: 155
6% less funds holding
Funds holding: 481 [Q2] → 451 (-30) [Q3]
6.47% less ownership
Funds ownership: 98.81% [Q2] → 92.35% (-6.47%) [Q3]
26% less capital invested
Capital invested by funds: $14.8B [Q2] → $11B (-$3.77B) [Q3]
31% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 84
50% less funds holding in top 10
Funds holding in top 10: 16 [Q2] → 8 (-8) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
36%
downside
Avg. target
$165
40%
upside
High target
$202
71%
upside
9 analyst ratings
8 positive
89%
0 neutral
0%
1 negative
11%
HC Wainwright & Co. Mitchell Kapoor 26% 1-year accuracy 43 / 164 met price target | 36%downside $75 | Sell Reiterated | 15 Jan 2025 |
Needham Gil Blum 16% 1-year accuracy 28 / 170 met price target | 71%upside $202 | Buy Reiterated | 14 Jan 2025 |
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 54%upside $182 | Overweight Maintained | 27 Nov 2024 |
Guggenheim Whitney Ijem 18% 1-year accuracy 7 / 40 met price target | 27%upside $150 | Buy Maintained | 7 Nov 2024 |
Baird Brian Skorney 17% 1-year accuracy 4 / 24 met price target | 64%upside $193 | Outperform Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 6 articles about SRPT published over the past 30 days
Positive
Seeking Alpha
4 days ago
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by the gene therapy. Despite past valuation concerns, Sarepta's current market cap of $11.4bn is justified, with potential for a >50% gain by YE25. Elevidys' high price and mixed clinical results raise concerns, but totality of evidence suggests it may be the best available treatment for DMD, with no immediate rivals.
Neutral
Business Wire
1 week ago
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. Financial Update* (preliminary and unaudited): Total net product revenue of $638.2 million for the fourth quarter and $1.79 bi.
Neutral
PRNewsWire
1 week ago
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
LUND, Sweden , Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference.
Positive
Zacks Investment Research
2 weeks ago
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
Neutral
Business Wire
2 weeks ago
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 13, 2025 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T. The presentation will be webcast live under the Events & Presen.
Neutral
Business Wire
2 weeks ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in December 2024. The equity awards were approved in accordance with Nasdaq List.
Positive
Reuters
1 month ago
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday.
Positive
Zacks Investment Research
1 month ago
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.
Neutral
Zacks Investment Research
1 month ago
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
Neutral
Business Wire
1 month ago
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. EMERGENE is a global study, and the primary endpoint is t.
Charts implemented using Lightweight Charts™